Press Release

Europe Epigenetics Diagnostic Market to Thrive at an Estimated 15.8% CAGR During 2025-30

The Europe Epigenetics Diagnostic Market size was valued at around USD5.4 billion in 2024 and is projected to reach USD13 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 15.8% during the forecast period, i.e., 2025-30, cites MarkNtel Advisors in the recent research report. This growth is mainly attributed to the increasing demand for the detection of multiple chronic diseases in their early stages, personalized medicines, reduced treatment costs, improved operational efficiency, and rapid innovations through continuous investments in research. Epigenetics diagnostics are performed to address these demands as they accurately determine the chronic diseases and help healthcare providers in initializing targeted treatment, thus increasing their efficiency while being cost-efficient.

Moreover, this growth is further fueled by the rising incidence of various chronic diseases in Europe. As per the WHO, approximately 20% of the deaths in Europe are linked to cancer, and around 32.5% of the deaths are linked to heart-related problems. Such incidents increase the awareness among people to invest in epigenetic diagnostics to ensure early detection before the spread of infected cells through personalized treatment. As a result, the demand for epigenetic diagnostics has increased as they describe the working behavior of cells and help the healthcare provider observe the progression of treatment. This results in the increased demand for such services in Europe.

Furthermore, the market is boosted by the continuous focus on research that improves the functionality of such services through technological advancements and also expands their use cases across various diseases. Various companies in this market have also adopted the use of AI and ML in their applications. This is because AI analyzes vast data, such as alterations in DNA methylation and histone modifications, to give valuable insights, and ML makes precise predictions based on the given data, that helps in providing precision medicines. This also helps in capturing the minute markers of any disease that are very difficult in manual analysis, which makes it easy to treat such problems in the early stages.

Therefore, the market has experienced significant growth in previous years due to improved treatment and cost-efficiency, and this growth will rise in the coming years amid the rising chronic diseases, aging populations, increasing healthcare awareness, and continuous government support, further states the research report, “Europe Epigenetics Diagnostic Market Analysis, 2025.”

Europe Epigenetics Diagnostic Market Segmentation Analysis

DNA Methylation Holds a Major Market Share

Based on the method used in epigenetics diagnostics, the market is further bifurcated into DNA Methylation, Histone Modifications, and others. Here, DNA Methylation leads the market with a share of around 60%. This is because testing the presence of methyl group (CH₃) on the DNA is very precise in this method which makes it easy for the healthcare providers to know about the disease, even in its starting phase. Moreover, this method has been around for longer, due to which it can be accessed easily across multiple regions, and that too at low costs, thus attracting more consumers. Therefore, due to its high accuracy & link with the disease, this method has been most widely used in the past years, and this dominance is expected to continue in the future as well.

Germany Leads Regional Epigenetics Diagnostic Industry

Regionally, Germany dominates the market with a share of around 36%. This is because of the presence of a huge population suffering from various chronic diseases. As per the Global Cancer Observatory, the number of new cases of cancer in Germany was around 6.05,805 in 2022. As a result, epigenetics diagnostics have gained popularity as they are used in detecting cancer, and such investments are further fueled by the high incomes in this country. In addition to this, more than 600 pharmaceutical companies are present in Germany, which are also prominent consumers of such services thus further increasing their demand. Therefore, the presence of a wide consumer base of epigenetics diagnostics is the main reason behind this region’s dominance, which is expected to remain in the forecast years as well.

Competitive Landscape

With strategic initiatives such as mergers, collaborations, and acquisitions, the leading market companies, including Diagenode, Oncgnostics, Epigenomics AG, PerkinElmer, Roche Sequencing Solutions, EpiCypher, Cambridge Epigenetix, Promega, QIAGEN, Agilent, Bio-Rad, Pacific Biosciences, and others, are looking forward to strengthening their market positions.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the region?
4. How has the industry been evolving in terms of geography & service adoption?
5. How has the competition been shaping up across the countries?
6. How have buying behavior, customer inclination, and expectations from services been evolving during 2020-30?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?